Medical Advisory Board
VIRxSYS' policy is to establish a Medical Advisory Board (MAB) for each product before it enters clinical trials. Additional advisors are consulted during preclinical stages.
VIRxSYS currently has an MAB comprised of key HIV experts who provide guidance in the design and execution of the Company's HIV clinical trials and in positioning VRX1273 and Lexgenleucel-T. The current members of VIRxSYS’ HIV Medical Advisory Board include:
|
Member
|
Affiliation
|
|
Steven Deeks, MD
|
University of California at San Francisco
San Francisco, California |
| Jose Gatell, MD |
University of Barcelona
Barcelona, Spain |
|
Carl June, MD
|
University of Pennsylvania
Philadelphia, Pennsylvania |
|
Christine Katlama, MD
|
Groupe Hospitalier Pitie-Salpetriere
Paris, France |
|
Daniel Kuritzkes, MD
|
Harvard University
Cambridge, Massachusetts |
|
Joep Lange, MD, PhD
|
Academic Medical Centre
Amsterdam, The Netherlands |
|
Michael Lederman, MD
|
Case Western Reserve University
Cleveland, OH |
|
Julio Montaner, MD
|
British Columbia Centre for Excellence in HIV/AIDS
Vancouver, British Columbia |
|
Robert Murphy, MD
|
Northwestern University
Evanston, Illinois |
|
John Phair, MD
|
Northwestern Medical Center
Evanston, Illinois
|
|
Richard Pollard, MD
|
University of California at Davis
Sacramento, California |
| Robert Schooley, MD |
University of California
San Diego, California |
| Pablo Tebas, MD |
University of Pennsylvania
Philadelphia, Pennsylvania |
The Company is in the process of assembling an MAB of cardiovascular experts to advise it on VRX1243.
"In today’s biotech environment, a company can succeed only if it reaches outside to get the best advice possible. We are fortunate to have assembled a fabulous group of the best and brightest HIV clinicians in the world for advice in our clinical trials and product positioning."
Dr. Tessio Rebello, VIRxSYS VP Clinical Affairs